PMID: 15217556Jun 26, 2004Paper

Antiangiogenic gene therapy for cancer treatment

Current Hematology Reports
A M Davidoff, Amit C Nathwani

Abstract

It is now well established that tumor growth and spread are angiogenesis-dependent processes. Therefore, inhibition of angiogenesis is likely to be an effective anticancer approach. A gene therapy-mediated approach to the delivery of antiangiogenic agents has several advantages, including the potential for sustained expression. However, several variables need to be considered when designing this approach. In addition to the choice of angiogenesis inhibitor, these approaches include the system for gene transfer and the target for gene delivery/site of inhibitor expression. This review summarizes the major alternatives within each of these categories and provides illustrative examples of their use in preclinical models.

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.